MEDIRISTA BIOTECHNOLOGIES AB has a total of 12 patent applications. Its first patent ever was published in 2009. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are MAINE MEDICAL CT, BARNEA EYTAN R and ANAMAR MEDICAL AB.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | Australia | 1 | |
#4 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Frostegård Johan | 5 |
#2 | Frostegaard Johan | 4 |
#3 | Frostegard Johan | 2 |
#4 | Johan Frostegard | 1 |
#5 | Liu Anquan | 1 |
Publication | Filing date | Title |
---|---|---|
WO2019215300A1 | Antibodies for use in combination therapy | |
WO2018220224A1 | Lipid-related antigens and antibodies directed against them | |
WO2011160845A2 | Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment | |
EP2542580A1 | Antibodies against phosphorylcholine in combination therapy with biologic agents | |
AU2009328507A1 | Oxidized cardiolipin as a novel pro-inflammatory factor |